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Abstract
Combination therapies are often needed for effective clinical outcomes in the management of complex diseases, but
presently they are generally based on empirical clinical experience. Here we suggest a novel application of search
algorithms—originally developed for digital communication—modified to optimize combinations of therapeutic
interventions. In biological experiments measuring the restoration of the decline with age in heart function and exercise
capacity in Drosophila melanogaster, we found that search algorithms correctly identified optimal combinations of four
drugs using only one-third of the tests performed in a fully factorial search. In experiments identifying combinations of three
doses of up to six drugs for selective killing of human cancer cells, search algorithms resulted in a highly significant
enrichment of selective combinations compared with random searches. In simulations using a network model of cell death,
we found that the search algorithms identified the optimal combinations of 6–9 interventions in 80–90% of tests, compared
with 15–30% for an equivalent random search. These findings suggest that modified search algorithms from information
theory have the potential to enhance the discovery of novel therapeutic drug combinations. This report also helps to frame
a biomedical problem that will benefit from an interdisciplinary effort and suggests a general strategy for its solution.
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Introduction
The problem of combination therapy has medical and
algorithmic aspects. Medically, we are still not able to provide
effective cures for most chronic, complex diseases that are the
main causes of death and disability, nor are we able to address the
progressive age-related decline in human functional capacity.
Algorithmically, when biological dysfunction involves complex
biological networks, therapeutic interventions on multiple targets
are likely to be required. Because the effect of drugs depends on
the dose, several doses need to be studied, and the number of
possible combinations rises quickly. For example, many cancer
chemotherapy regimens are composed of 6 or more drugs from a
pool of more than 100 clinically used anticancer drugs and
exploring even larger combinations might be justified [1]. If we
were to study all combinations of 6 out of 100 compounds
(including partial combinations containing only some of these
compounds) at 3 different doses we would have 8.9610
11
possibilities. This example shows that the problem requires a
qualitatively new approach rather than simply more efficient
screening technology.
Combined drug interventions are a common therapeutic
strategy for complex diseases such as hypertension and cancer.
As pointed out recently for cancer therapy [2], most therapies
were initially developed as effective single agents and only later
combined clinically. A possible approach to the exploration of new
therapeutic activities not present in individual drugs is based on
the exhaustive study of all possible combinations of pairs of
compounds [3]. This ‘‘brute force’’ approach has detected many
interesting novel pairs of compounds [3], but the resulting
exponential expansion in the number of possibilities precludes
the comprehensive exploration of larger combinations.
Several authors [4,5] have recently argued that the future of
combination therapy lies in the development of accurate
quantitative network models that capture the mechanistic
interactions of cellular and organism physiology. Fitzgerald et al.
[5] acknowledge that we do not yet know what these models will
look like, and that systems biology research is still data-limited for
this purpose. Indeed their recent review does not report any
successful application of this approach to combination therapies.
Here we suggest a novel solution to the problem of combination
drug therapy, making use of search algorithms originally
developed for digital communication. When modified in several
key aspects, these search strategies can be used to find more
effective combined therapeutic interventions without the need for
a fully factorial experimental design (testing all possible combina-
tions of drugs for all selected doses). These algorithms may also
provide a framework upon which information from system-wide
molecular data (e.g. transcriptomics and metabolomics) and from
mechanistic computational networks models can be superimposed.
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To understand the motivation for our work it is important to
consider that, even if simulations might play a role, the intended
use of the algorithms is not entirely in silico, but partially in vivo or in
vitro, using high-throughput biological measurements in organisms
or isolated cells, respectively. This approach becomes increasingly
relevant because high-throughput measurement technology,
initially developed by drug companies for the screening of large
libraries of compounds in multi-well plate formats, is now more
and more available to the scientific community.
It is useful to regard the information processing by our
experimental systems as parallel biological computations, since the
algorithms we are using are indeed derived from algorithms that were
implemented in silico in other scientific fields. Parallel measurements
are suitable for multi-well high-throughput technology.
There are requirements regarding the computational complex-
ity of the algorithms that limit the choice of suitable approaches.
These requirements are discussed in more detail in the Results.
Both the number of operations and computational costs unique to
in vivo/in vitro algorithms should be considered.
Algorithm design requires the application of an appropriate
structure to the data. Although there are many options to
represent the space of possible drug combinations, we used a tree
representation with drug combinations as nodes linking to all
possible additions of one drug in the next level. Individual drugs
form the base of the tree and combinations of maximum size are at
the top (see Algorithms section in the Results). When exploring the
drug combination tree going from smaller to larger combinations,
as in the algorithms we suggest, we are giving more weight to
lower-order drug interactions. This is consistent with data
available on adverse drug interactions, which are reported mostly
for two-drug combinations [6,7]. Estimating the optimal size of a
combination is a different problem, examined in detail in the
Discussion. The beneficial effect of a combination is also due to
additive components (not depending on interactions) and to
multiple higher-order effects.
The search algorithms we suggest are derived from sequential
decoding algorithms. These were chosen in part because of
similarities among the data trees to be searched in the biological
and decoding applications (see again the Algorithms section in the
Results). Sequential decoding algorithms are used for convolu-
tional codes, in which nearby nodes in the data tree are related,
similarly to different but partially overlapping combinations of
drugs.
Another feature of sequential algorithms that fit our purposes is
the use of a list-based memory of the path taken to reach each
node. We provide in the Discussion a detailed argument
suggesting that a suitable algorithm should be able to integrate
all available information on the state of the system with that
obtained by iterative measurements. The integration should take
place at every iteration within the algorithm, rather than being a
weighted average of different methods applied separately. The
presence of the updated list as a guide for each iteration provides
our algorithms with a natural mean of information integration.
Both the fully factorial dataset we show in Figure 1 and the
complex structure of the biological networks that are being
reconstructed in systems biology supports this expectation of
frequent non-linearities in phenotype measurements along the
data tree. Therefore we are interested in algorithms that can
search within a solution space presenting substantial non-
linearities. If the relation among drugs in a combination were
linear, the best algorithm would simply determine the best dose in
single drug measurements and use these to obtain the best
combination. If, on the contrary, non-linearities were extreme, the
use of stochastic algorithms might be preferable. Stochastic
algorithms (see also Discussion) can cope with multiple local
minima in the solution space, but they do so by incorporating a
random element. This requires a price in terms of computational
cost, and the performance of stochastic algorithms is therefore
often not as good as that of more tailored algorithms [8,9]. The
algorithms we suggest can cope with moderate and variable non-
linearities by going back to previous nodes in the tree.
Starting with the stack sequential algorithm, which was
developed to search for optimal decoding in the field of digital
communications [10], we describe and test algorithms that can be
used to search for an optimal combination of a sizeable number of
drugs, by testing only a small subset of all possible combinations.
The algorithms are useful for large combinations, where collecting
fully factorial datasets is not feasible. We present results obtained
from simulations in a computational model of cell death and from
experiments using two models with complementary biological
properties: (i) restoring the decline with age in heart function and
exercise capacity in Drosophila melanogaster;and (ii) selective killing of
human cancer cells.
The first in vivo experimental model has the advantage of
including the complexity of whole organism interventions, while
the second in vitro model has the potential for markedly higher
throughput testing. These models are also representative of two
different general types of multi-drug interventions: one type aims
at improving function, while the other is based on the induction of
cell death, a selective disruption of network function. Results
suggest that optimal or near-optimal combinations of compounds
can be found in these systems with only a small fraction of the
number of tests as a fully factorial design, and with significantly
higher efficacy than random searching. In summary the
contributions of this work are:
– Constructing a novel problem statement for the search of drug
combinations, using a novel approach to systems biology (see
also Text S1).
Author Summary
This work describes methods that identify drug combina-
tions that might alleviate the suffering caused by complex
diseases. Our biological model systems are: physiological
decline associated with aging, and selective killing of
cancer cells. The novelty of this approach is based on a
new application of methods from digital communications
theory, which becomes useful when the number of
possible combinations is large and a complete set of
measurements cannot be obtained. This limit is reached
easily, given the many drugs and doses available for
complex diseases. We are not simply using computer
models but are using search algorithms implemented with
biological measurements, built to integrate information
from different sources, including simulations. This might
be considered parallel biological computation and differs
from the classic systems biology approach by having
search algorithms rather than explicit quantitative models
as the central element. Because variation is an essential
component of biology, this approach might be more
appropriate for combined drug interventions, which can
be considered a form of biological control. Search
algorithms are used in many fields in physics and
engineering. We hope that this paper will generate interest
in a new application of importance to human health from
practitioners of diverse computational disciplines.
Search Algorithms for Drug Combinations
PLoS Computational Biology | www.ploscompbiol.org 2 December 2008 | Volume 4 | Issue 12 | e1000249Figure 1. The Drosophila fully factorial dataset. The number on the right of each combination is a summary score (z-score) obtained from the
three phenotypes measured in aged flies: maximal heart rate, exercise capacity and survival. Scores are ordered in descending order with the best on
top. The 4 columns show, from left to right, the effects of using 1, 2, 3 and 4 drugs in combination. The effects do not appear to be additive but
complex interactions are present. Larger combinations have significantly larger z-scores.
doi:10.1371/journal.pcbi.1000249.g001
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factorial dataset) sufficient to solve the problem conclusively.
– Constructing a computational method to solve the problem
approximately with fewer experimental measurements (the
search algorithms). The suggested algorithms are modeled on
algorithms already used in other fields, while our main original
contribution is in their novel application.
– Providing additional experiments to support the generality of
the approach.
Results
A Fully Factorial Dataset Obtained in Drosophila
A fully factorial dataset is a dataset where all possible
combinations of drugs for the selected doses are tested. The
dataset was obtained from biological measurements in a living
organism, Drosophila melanogaster (the fruitfly).
A detailed account of the Drosophila cardiac aging model was
presented previously [11]. We performed an initial screen of
compounds for their effects on cardiac aging in Drosophila, selected
for their general effects on multiple biological functions, previously
demonstrated low toxicity and, for some compounds, known
effects on aging in other models.
After screening 44 compounds individually at multiple doses (a
total of 300 groups, each composed of 10–20 flies), we chose two
doses each of four compounds for more comprehensive measure-
ments of their combined effects on three age-related phenotypes:
the declines in maximal heart rate, exercise capacity and survival.
The selected compounds (see Methods for doses in the fly food)
were: doxycycline, a broad spectrum antibiotic and inhibitor of
mitochondrial protein synthesis [12]; sodium selenite, an essential
trace mineral and cofactor of many metabolic enzymes; zinc
sulfate, another trace mineral and cofactor of many metabolic
enzymes; and resveratrol, a phenolic antioxidant with an action on
proteins linked to aging [13].
The compounds were fed to flies from the age of 7 days to the
age of 30 days. We have previously shown cardiac physiological
changes with age in 30 day-old flies [11]. The maximal heart rate
was measured at the age of 30 days. Climbing velocity was
measured every 5 days between the ages of 15 to 30 days, using a
non-invasive procedure. We studied 10 male flies for climbing and
10 female flies for the cardiac measurements. Survival to 30 days
was also measured in these flies. Figure 1 illustrates the fully
factorial dataset consisting of 81 combinations of 4 drugs, using 2
doses for each drug (1 control, 8 individual tests, 24 groups of 2
combined drugs, 32 groups of 3 combined drugs and 16 groups of
4 combined drugs).
The number on the right of each combination in Figure 1 is a
summary score (z-score) obtained from the three phenotypes
mentioned: the declines with age in maximal heart rate, climbing
velocity and survival. Each value was normalized by dividing by a
weekly control, then for each group subtracting the population
mean anddivingbythepopulationstandard deviation. The z-scores
from the three phenotypes were then averaged to yield a summary
z-score that equally weights each of the three measurements.
Analysis of Figure 1 shows that, with a larger number of drugs in the
combination, there is a statistically significant increase (p,0.05) in
the percentage of treatments that have an improved z-score
compared with untreated controls of the same age.
The landscape (see section in Discussion on control landscapes)
obtained from this dataset has 7 local maxima and 1 global
maximum in the phenotype z-score. The maxima correspond to
drug-doses configurations for which the z- score decreases by
changing any of the drugs by a single dose. We have also
calculated the basin of attraction, i.e. the number of drug-doses
configurations that will end up in a given maximum by following
the maximal increase in z-score, and found that the global
maximum corresponds to the largest basin. This is an example of
how landscape terminology can be used to define moderate non-
linearities suitable for the algorithmic approach we suggest.
The Algorithms
Sequential decoding algorithms and the stack sequential
algorithm. In this section we introduce the drug combination
optimization algorithms and show how they relate to the algorithms
used in sequential decoding. Fully factorial datasets, where every
possible drug combination is tested, grow exponentially with the
number of drugs (n). See Text S1 for the relevant equation and an
example dataset. In computational terms we say that the complexity
is O(a
n). The O-notation indicates the order of growth of an
algorithm basic operation count as a function of the input size. An
exponential growth is not practical for large n, therefore our aim is
to find algorithms with improved efficiency, for example with a
linear dependency on n, expressed as O(n).
The ‘‘stack sequential algorithm’’ was first proposed by
Zigangirov and Jelinek for the sequential decoding of noisy digital
signals [10,14]. As pointed out by Johannesson and Zigangirov
[15], the word ‘‘stack’’ is used instead of the proper word ‘‘list’’
only for historical reasons. It is the most basic and simplest to
describe of the sequential decoding algorithms.
The problem of finding the optimal estimate of the encoded
sequence is described as a walk through a tree. To appreciate the
analogy with the search for the optimal drug combination, the tree
shown in Figure 2 can be compared with the trees used in one of the
original descriptions of the stack sequential algorithm [14]. An
alternative version of the tree, the ‘‘trellis’’ depiction shown in
Figure 3, eliminates nodes representing redundant drug-dose
combinations.
The stack is a sorted list of all examined combinations (best on
top). The description of the stack sequential algorithm of the
Jelinek paper [14] corresponds to the following adaptation to our
problem:
S1 - At the beginning of the process the list contains only
the measurement in the absence of any drug (the root of
the tree of Figure 2).
S2 - The search is extended from the top of the sorted
list. An extension corresponds to moving up one level in
one of the branches of Figure 2. Combinations already
used are ignored for future extensions.
S3 - The search ends when a combination of maximum
size is reached. This is equivalent to reaching the top of
the tree of Figure 2.
Since we are looking for the best combination, and not for the
best path, in our case we do not delete any measured combination
from the list. Instead, when a combination has already been used
for extension in the tree, we move to the next combination in the
sorted list. As indicated in Figure 2, we do not combine different
doses of the same drug with each other, to limit the size of the
search, but this is not an essential feature.
This algorithm is effective in searching combinations where the
effect is not purely additive, because it can overcome non-
linearities by going back to previous nodes in the tree.
Three classes of algorithms for searching the data
tree. A family of related algorithms can be derived from the
basic structure of the stack sequential algorithm described in the
Search Algorithms for Drug Combinations
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different trade-offs between complexity and performance. This is
similar to the case of sequential decoding. Examples of other
algorithms that are part of the sequential decoding family, with
trade-offs partially analogous to those we have implemented, are
the Fano algorithm and the Creeper algorithm [15].
This family of algorithms can be divided into three basic classes
that differ in their approach to the data tree of Figure 2. Figure 4
shows the structure of these three classes. The class that follows the
same direction of search within the data tree as the stack sequential
we call SS; the class that searches the tree in the other direction,
from the top down, we call TD; and the class combining both
approaches (starting as SS and continuing as TD) we call SS-TD
(see Figure 4). Below we describe the implementation of each class
used in this paper, which we call SS9,T D 9 and SS-TD9.
Notation. Let DRUGS represent the set of all drugs under
consideration, and let DOSES represent the set of all possible doses.
Additionally, let n be the number of drugs and m the number of
possible doses.
Let a drug be denoted by D while a dose is represented by d.
The ordered pair (D, d) represents the drug along with its dose. Let
C represent a collection of drug-dose pairs (a drug combination).
Let function Score(C) assign a score z to the drug combination C
and save (C,z). Let C_LIST=[(C1 z1), (C2 z2), …] represent a list
of drug combination-score pairs. For any collection Ci, we refer to
the cardinality of the collection |Ci| as size (size of the
combination).
The problem of selecting Copt, the optimal drug combination
that maximizes Score(C) is a combinatorial optimization problem
for which we propose a number of algorithms.
It is important to note that Score(C) is the only step that is not
executed in silico but is measured in vivo or in vitro (biologically). A
ranked summary list with all the measured combinations is
obtained at the end of the procedure.
SS9 algorithm. This algorithm starts by evaluating all
individual drug-dose pairs, and then incrementally adds (D, d)
pairs extending from the pair producing the maximal benefit. If at
the i-th step, the addition does not increase the benefit, the
algorithm backtracks to choose the next most beneficial
combination from the (i21)-th step. The informal steps (S) of
the algorithm, which are also presented in pseudocode in Figure 5,
are as follows:
S1 Evaluate all drugs individually at all doses and rank them
according to the biological score.
S2 Save only the best dose for each drug in the single drug list.
S3 Extract the best single drug and call it Cbest.
S4 Combine Cbest with all other drugs (for all doses), increasing
the size of the combination by 1 drug, measure the biological
scores, and save the list of combinations of this size. At this
Figure 2. Tree representation of the data. Letters indicate drugs and numbers indicate different doses of each drug. The root (level 0) is the
control (no drugs), level 1 is composed of individual drug measurements (singles), level 2 is composed of combinations of two drugs (couples) and so
on. The level corresponds to the size of the combination. Both this tree and the tree of Jelinek [14] contain repetitions.
doi:10.1371/journal.pcbi.1000249.g002
Figure 3. Trellis-like representation of the data. The data can also be represented as a trellis-like structure, without repetitions. The two data
representations shown in Figures 2 and 3 (tree and trellis-like, respectively) correspond to the alternative data representations used for coding
algorithms [15]. Figure 3 should also be compared to Figure 1, showing the Drosophila dataset. In the more complex Figure 1 the trellis is oriented
from left to right and the edges (lines) are not shown directly (for simplicity) but should be seen as connecting each combination with those on the
next level that contain the same set of colors. Each color indicates a different drug-dose pair. Additionally, Figure 1 shows ordering according to the
summary score (z-score).
doi:10.1371/journal.pcbi.1000249.g003
Search Algorithms for Drug Combinations
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Figure 2.
S5 If the score of one of the new combinations is better than
Cbest use this combination as the new Cbest and return to S4.
If none of the new combinations is better than Cbest
backtrack to the next best combination in the list of the
previous size, call it Cbest and return to S4.
S6 Limit the number of backtracks to a specified value.
S7 Repeat S4 to S6 until the maximum size for the combinations
is reached.
In this implementation we introduced two features that make
the algorithm more appropriate for our application.
In S2 we choose only the best dose to extend from for the
individual drugs. This is because if we need to return to this level
after having combined the best single drug with all the others, it
means that all lower order interactions (that is couples) were not
beneficial, and therefore we prefer to change drug rather than
trying a different dose of the same drug.
In S6 we limit the number of backtracks to limit the cost of the
algorithm. We used a limit of 2 in all the experiments presented.
This limit can be increased if the throughput of the technology we
use for the biological measurements allows it. If we wish to
increase this limit, we can make a choice among possible
implementations that either backtrack only one level at a time
or jump to any level that ranks next in the summary list. These
implementations would have different complexity.
While SS9 moves up in the data tree the number of measured
combinations declines (see Text S1). This algorithm therefore gives
greater weight to lower order combinations in deciding which
branches of the data tree we should explore. This is consistent with
the expectation that lower order interactions among drugs are
likely to be stronger than higher order interactions, as mentioned
in the Introduction.
The experimental complexity of this implementation (both best
and worst case) grows as O(n
2) for the number of drugs, and O(m)
for the number of doses (see Text S1). Increasing the backtracking
limit we might reach, in the worst case, the same complexity of the
fully factorial, that is O(a
n).
For algorithms including an in vivo or in vitro (biological) step we
also have to consider other types of computational complexity,
beside the number of operations. Biological measurements can
take a very long time compared to any in silico step (several weeks
are required for the Drosophila experiments) and may be limited
by sample availability. This type of cost needs to be calculated
separately for each application. In these algorithms there are also
iterated cycles composed of biological measurements that can be
done in parallel. All combinations formed in S4 above, extending
from the best scoring combination, can be measured in parallel.
Parallelization suits existing screening technology (e.g. multi-well
plate robotics) but the number of cycles can also be limiting, again
depending on the specific biological application.
TD9 algorithm. The rationale motivating the development of
top-down searches within the data tree is based on both the higher
scores for larger combinations shown by the Drosophila fully
factorial dataset of Figure 1 and the reduced number of
combinations of higher order in all fully factorial datasets of this
type, shown in Text S1. These two factors led us to expect a higher
probability of finding desired scores within combinations of larger
size, and supported the development of algorithms with a higher
proportion of measurements in this region of the data tree. We can
also easily modify the algorithms to stop once a combination with
the desired score is found, and therefore we wish to increase the
probability of finding these combinations early in the search.
The first steps are the same as those of the SS9 algorithm (see
Figure 6 for pseudocode):
S1 Evaluate all drugs individually at all doses and rank them
according to the biological score.
S2 Extract the best single drug and call it Cbest.
After the individual measurements the TD9 jumps to search
within combinations with the largest size and moves progressively
down the data tree from there:
S3 Combine Cbest with all other drugs (for all doses) for
combinations of maximum size, measure the biological scores,
and save the ranked list of combinations. At this step the
algorithm moves to the highest level in the tree of Figure 2.
Figure 4. The three classes of algorithms. Three types of strategies for searching the data tree. In our case the starting point was an exhaustive
set of measurements of all the single drugs and doses we selected. It is also possible to start the tree search at a higher level, for example after having
tested all the couples.
doi:10.1371/journal.pcbi.1000249.g004
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S5 Count the occurrences of all drug-dose pairs and save them
in a new list.
S6 Save only the most frequent dose for each drug in the new list.
S7 Create all possible combinations of the next smaller size,
using the drugs in the list of most frequently occurring drug-
dose pairs, and measure the biological scores. At this step the
algorithm moves down one level in the tree of Figure 2.
S8 Return to S4 until reaching size 2.
The complexity of this algorithm is O(a
n), and is therefore
suitable only for searches within a small number of drugs. It is
described only to make the construction of the next algorithm clear.
SS-TD9 algorithm. This algorithm aims to combine the
desirable features of the two preceding algorithms. It starts as a SS9
up to combinations of J drugs and then jumps to the largest size
combinations like the TD9. See Figure 7 for pseudocode.
The computational cost is limited by design, because we choose
J so that the cost is always within 10% of the corresponding SS9;
therefore the SS-TD9 has the same complexity as SS9, O(n
2).
Testing the Algorithms in the Drosophila Dataset (In Vivo)
The fully factorial dataset of Figure 1 was used to test the SS9
and SS-TD9 algorithms. Both algorithms were successful in finding
the best combination (and 3 of the 5 best combinations) with a
lower cost compared to an exhaustive search (24 and 27 tests out
of 81 for the SS9 and SS-TD9 respectively).
Testing the Algorithms with Computational Simulations
on the Apoptosis Network (In Silico)
We performed computational simulations of multiple interven-
tions on the apoptosis network using the two algorithms described
above. The computational model is based on the apoptosis
network, hsa04210, of the KEGG database (http://www.genome.
jp/kegg/). We used the discrete apoptosis model described in our
previous publication [1], where the discrete state of proteins at
each node is determined by the strength of a signal from the
neighboring nodes according to a logarithmic rule. In this model,
the final life/death signal is calculated following the signaling in
the directed network up to a final output node. The effect of a drug
on a given node is modeled by changing the activity on that node
Figure 5. SS9 pseudocode.
doi:10.1371/journal.pcbi.1000249.g005
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We simulated selective killing of cells caused by drugs acting on
the apoptosis network. All possible interventions on 6, 7, 8, and 9
proteins, using 3 doses, were simulated. We used the dataset
containingallpossibleinterventionstostudytheefficacyforselective
killing of the two algorithms (SS9 and SS-TD9), compared with
randomly selected combinations of the same size (see Figure 8).
Both algorithms were significantly more efficient than random
tests (p,0.0001). The SS-TD9 was clearly superior in the
frequency of identification of the very best combination, but the
SS9 also performed well (Figure 8). If a purely additive strategy
were the optimal one, the SS9 would find it, with no backtracks.
However, this does not seem to be the case. In the fully factorial
tests, larger combinations of up to 9 interventions were more
effective than single or two-drug interventions in finding the most
selective solution (p,0.0001).
We also performed an alternative simulation changing a large
number of parameters (see Methods section), to test the robustness
of these findings, and were able to confirm the behavior shown in
Figure 8.
As suggested by the number of top combinations found by
random sampling in Figure 8, these fully factorial datasets
contained multiple maxima. We investigated a different group of
30 fully factorial datasets (using 8-drug combinations) where
maxima were very few (less than 0.05% of the total). Not
surprisingly, in these simulations, random tests never found the top
combinations. However, top combinations were found in 30% of
the tests by the SS9 algorithm and in 80% of tests by the SS-TD9
algorithm. Furthermore, the distances of the best solutions found
Figure 6. TD9 pseudocode.
doi:10.1371/journal.pcbi.1000249.g006
Figure 7. SS-TD9 pseudocode.
doi:10.1371/journal.pcbi.1000249.g007
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9.261.4 (mean6SEM) for random tests, 4.761.2 for SS9 and
0.360.1 for SS-TD9. All differences between groups were
statistically significant (p,0.01).
Testing the Algorithms in Cancer Cell Lines (In Vitro)
Two lymphoma cell lines, RS 11846 and DoHH2, were used.
These cell lines were chosen for the simplicity of the culture
conditions, aiming to validate the method. Future tests will explore
selectivity including also normal cells and cells with different
tumorigenic potential. The number of viable cells was measured
using a luminescence test for ATP (ATPlite, PerkinElmer). We used
three different doses (for 60 hours) of six drugs affecting cell viability:
Vincristine, Etoposide, Rituximab, Apogossypol, Dexamethasone
and qVD-OPH. The first five drugs can induce cell death as
individual interventions while the last is an inhibitor of cell death.
We compared the SS-TD9 algorithm with random combinations.
After 36 tests for each cell line using individual doses we measured
91 combinations using the SS-TD9 algorithm and 107 randomly
chosen ones (107 was the maximum theoretical number of tests
required by the algorithm). The steps followed the order: couples,
triplets, sextuplets, quintets, quartets. The SS-TD9 selectivity (mean
21.362.4%) was markedly better than that in the random approach
(mean 1.962.5%, p,0.0001). Furthermore, none of the five most
selective combinations could have been found with the traditional
approach of combining only drugs that are cytotoxic individually,
since these five combinations all contained qVD-OPH. The cancer
cell results are shown in Figure 9.
Discussion
It might be argued that each drug combination and biological
system will require a different search algorithm and that there is no
reason to expect universality. The results reported here, obtained
with very diverse systems and compounds, suggest otherwise.
Additional rationale supporting the existence of optimization
algorithms with general applicability to biological networks is
provided by the shared properties of these networks (such as a
scale free distribution [16], robustness and evolvability [17]).
In future studies it will be desirable to develop formal methods
to assist in the choice of the individual drugs to be considered by
the algorithms, and to determine which doses to study. It is
reasonable to consider several doses spanning the IC50 or EC50,
but in large combinations we should expect to use lower doses than
those common for the same drugs as single agents. At least initially
the compounds more appropriate for use in the algorithms are
FDA approved drugs and well-known supplements, for which the
preferred dosage as single agents is already known.
Alternative Approaches
Several concepts (e.g. synergy) have been developed in the past for
the study of combinations of mainly two drugs [3,18,19]. Synergy is
useful but it is not a necessary property for the optimal combination
Figure 8. Simulations using 6 to 9 drugs. The 3 approaches described (randomly chosen group of combinations, SS9 algorithm and the SS-TD9
algorithm) are compared. We report the % of tests (average6SEM from 75 simulations) that can find the best combination, for interventions using 6
to 9 drugs. The cost is expressed as the number of tests. The decline in success rate with an increasing number of drugs for the random and SS9
groups is probably explained by the decreasing proportion of the total possible combinations tested (shown as decreasing ratio). This is not the case
for SS-TD9, but we do not yet know if this is a general property of the algorithm. The total number of possible combinations increases exponentially
with the number of drugs and becomes quickly too large for our biological measurements (for example with 9 drugs the total is 262144, see
rightmost column) and therefore justifies the necessity of an algorithm to limit the experimental space. The maximal cost for the two algorithms
(bottom line) is still within the reach of many experiments. This simulation was done using 3 doses per drug.
doi:10.1371/journal.pcbi.1000249.g008
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includes the case where this optimal result is due to synergy.
A PubMed search for algorithm and ‘‘combination therapy’’
identified 101 papers. All of the abstract and the papers that
appeared relevant were reviewed. Most papers describe sets of
clinical rules derived from clinical experience or from randomized
clinical trials, relevant to combinations of 2–3 drugs, to be
implemented by physicians. These approaches were called
therapeutic, diagnostic, treatment, management or decision
algorithms. A few papers [20–22] describe algorithms to be
implemented in silico and providing guidance for some drug
combinations of small size, using disease specific information.
None of these papers described search algorithms suitable for
partially in vivo or in vitro searches as those we describe.
A recent interesting paper [23] describes the use of stochastic
algorithms for the search for optimal drug combinations. The
methods described are not directly suitable for parallel biological
measurement but stochastic methods, for example genetic
algorithms, can certainly be adapted for this purpose.
Size of Drug Combinations
Several current cancer chemotherapy regimens are composed of
combinations of 6 or more drugs. Examples, indicated by their
acronyms and followed by the respective number of drugs, are:
BEACOPP 7, ChlVPP/EVA 7, MACOP-B 6, ProMACE-
CytaBOM 9, MOPPEBVCAD 10, m-BACOD 6 [24–27].
When the algorithms suggested here search within a pool of
drugs the best combination found can be of any size. In other
words when searching within all possible combinations of different
doses of 10 drugs, it is possible that the best combination emerging
might be composed of only 3 drugs, as for example in the
Drosophila dataset of Figure 1.
An important question whether we can determine the
maximum number of compounds that a combination should
have. Our opinion is that such a maximum limit cannot be set as a
general rule, based on the following considerations:
– Our algorithms can be used for combinations of any
compound with biological activity, including not only drugs
but also natural products. There are several dietary compo-
nents, for example wine, that have been suggested to have, at
certain doses, beneficial effect on human health [28,29]. These
dietary components contain a large number of partially
unknown different chemical compounds.
– Toxicity does not necessarily limit the size of a combination, as
discussed in the safety section that follows.
– The complexity of many biological networks leads us to expect
that only an intervention on a large number of nodes might allow
us to optimize their function. Our knowledge of these networks is
however still incomplete and no precise calculations are possible.
Information Theory and Search Algorithms for Optimal
Drug Combinations
We can think of drug interventions as transmitting information
to biological networks. When we search for optimal drug
Figure 9. Cancer cell experiments and the SS-TD9 algorithm. The colors indicate the selectivity of the drug interventions and the aim is to find
treatments with high selectivity for one of the cell lines, shown as dark blue. The red shades are partially selective for the other cell line. After
measuring the effects of individual drugs, shown as equally distributed in their effects on the two cell lines (Single column), we follow the steps of the
SS-TD9 algorithm on top and compare it with random testing of combinations of the same size in the lower part of the figure. A statistically significant
enrichment of the desired selective combinations is shown.
doi:10.1371/journal.pcbi.1000249.g009
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domain of information theory) is important, and it is therefore not
surprising that some modified algorithms from digital communi-
cations, which are used to efficiently decode signals in the presence
of noise, might be applicable. There are, however, also several
differences that require modifications to these algorithms.
Among the similarities with the digital communication applica-
tions of sequential decoding algorithms are the following: the
partial exploration of a tree of possible solutions, the dependence
of the score on the previous steps of the algorithm, the objective of
maximizing the score and minimizing the cost, and the use of an
ordered list to store the solutions.
Among the differences are the following: the partially different
data structure to be explored and the related possibility of jumping
to different parts of the tree and even ignoring some steps (for
example, SS-TD class algorithms are not used for decoding and
are unlikely to be useful), and the tendency of the largest
combinations to have higher scores. The computational cost is also
partially different. For example memory is not a limiting factor but
the number of tests and the time required by each step are.
Safety
We would also like to discuss the drug safety implications of the
use of drug combinations in general and of our approach more
specifically. Of the two main types of adverse drug events, type A
adverse events represent the majority [30]. These are dose-related
and arise from the pharmacological action of the drug [30]. Type A
adverse events are not necessarily increased in combinations if we
use reduced doses of each drug. Furthermore, the objective metric
of thealgorithm canincorporate the reductionofadverse effects. An
example is the choice of selective cell death for the cancer cell
measurements we report, rather than just the killing of cancer cells.
If we were to find a large therapeutic combination that had an
extremely selective action only on cancer cells (or on a particular
cancer), this would have a greatly improved safety profile compared
to any of the existing chemotherapeutic regimens.
The second major type of adverse drug events, type B, is much
more rare and not dose-related. These adverse events are at least
in part genetic [30] and should be ameliorated by including
genomic data as one of the components of our algorithms in future
implementations. As for single drugs, medication safety is always a
balance of risks and benefits. Some types of cancer have a
prognosis of only a few months. Hence the risk-benefit analysis
cannot be discussed for drug combinations in general, but depends
on the type of disease, the type of drugs involved and the condition
and informed choice of each patient.
Drug interactions are a known cause of adverse events, but,
given that multi-therapy is common and essential for many
patients (most hospitalized patients receive at least six drugs [31]),
it is preferable to develop formal methods of assessment, as we
suggest, rather than leaving the development of multi-therapies to
the empirical decision of individual physicians.
Nonlinearities and Control Landscapes
We have mentioned in the Introduction that one of the
desirable features of these algorithms is the capacity of dealing
with non-linearities in drug combinations. The most suitable
measures of non-linearity can be obtained by building an n-
dimensional ‘‘control landscape’’, where the dimensions are the
drugs, at different doses. The notion of landscape represents a
commonly used concept in the analysis of many complex systems
encountered in physics, biology, computer science and engineering
[8]. Several features can provide a quantitative characterization of
these landscapes, such as the density of optima [32] or the
ruggedness [8]. The ruggedness measures the correlation of the
biological score to be optimized in ‘‘neighboring’’ positions and
can be obtained by defining random walk processes in the drug
configuration space, and by calculating the correlation length of
the score in such processes [32]. The landscape could also be
modified using system-wide biological data (omic data) to reduce
non-linearities. This omic warping is analogous to approaches
commonly used in physics.
While the tests in cancer cell lines reported here do add evidence
supporting the efficacy of the suggested algorithms, it would be
desirable in future experiments to give priority to the collection of
fully factorial datasets. Comparisons with random samples have
several limitations, including the fact that the true optimum is
unknown. Fully factorial datasets are, when experimentally feasible,
more informative, allowing the characterization of the landscapes
and the evaluation of alternative search algorithms.
Integrating Other Information in the Algorithms
There is a more general rationale supporting the use of
algorithms integrating information on the state of the system with
iterative measurements. The Artificial Intelligence community
realized at the beginning of the 90s that robots could not manage a
complex environment utilizing only explicit models of reality [33].
An alternative approach that started from simpler stimulus-
response algorithms was more successful and was later integrated
with the older models in hybrid architectures [33]. The
proponents of this approach (among them Rodney Brooks) argued
that this process was similar to the evolution of the nervous system,
which is based on stimulus-response mechanisms of increasing
complexity in lower invertebrates, integrated (but not replaced) by
representations of reality within the brain of higher organisms. See
also Figure 1 of Pfeifer et al [34]. Similarly we can start from
‘‘stimulus-response’’ algorithms and then improve them using
progressively more detailed and mechanistic models of biological
networks. The algorithms we have described are composed of
several iterations, each depending on the previous response of the
system. As pointed out [35], control and optimization algorithms
do contain information about the system, when effective, but only
in an implicit form. This approach, used to control very complex
and partially unknown systems by natural evolution and by
possibly the most ambitious attempt to emulate evolution, building
intelligent machines, is a general strategy that motivated the
development of our algorithms.
It is useful to consider how system-wide molecular data (such as
genomic, proteomic, metabolomic and transcriptomic data) could
be used in the context of our searches. These omic datasets could
affect the ranking in two ways: as objects of multivariate analysis
and as parameters of mechanistic network models, as in Figure 10.
Pattern recognition methods and multivariate statistics can be
used to analyze system-wide molecular data [36]. With these
models, it could be possible to distinguish the groups studied in a
multi-dimensional representation. For example, it might be
possible to test whether a combination brings the metabolic and
transcriptional profiles of treated cells or organisms closer to that
of the target state and by how much. A similar approach was used
in a recent publication by Lamb et al [37], where a single score
was obtained to represent the response of a breast cancer cell line
to drugs. The score was a summary of multivariate biological data
(microarrays). This statistical approach is justified by the fact that
not all molecular information is included in the network models,
but is expected to play a lesser role as the comprehensiveness of the
models improves.
Metabolic models similar to that described in our recent paper on
Drosophilahypoxiamayalsoplayarole[38].Geneexpressiondata of
Search Algorithms for Drug Combinations
PLoS Computational Biology | www.ploscompbiol.org 11 December 2008 | Volume 4 | Issue 12 | e1000249metabolic enzymes and NMR measurements of metabolites for
individual treatments could be added to the model and the effect of
combining the interventions can be simulated. The model can
provide summary measures that have an important effect on
function, such as ATP production, and are ideally suited as
weighted modifiers of the algorithm rankings. For the cancer
experiments we could iteratively modify the apoptosis computa-
tional networks described in our recent paper [1]. To reflect the
results of intervention experiments, one could add to the model the
targets of all the drugs used, and use microarray data specific for the
cell types to modify the simulations. As our biological knowledge
improves, mechanistic models should play an increasing role.
The algorithms described here are suitable as frameworks to
integrate imperfect information from different sources. The
information can be used to modify the rankings and fully factorial
datasets can be used to assign weights to different types of
information. For example, if the cytoprotective protein Bcl-2 is
overexpressed in a target cell type or if network simulations
indicate that it is an important control node, one could modify the
ranking metric of combinations including drugs acting on it and
test whether this improves the efficiency of the algorithms within
our fully factorial datasets.
Potential Applications to Personalized Medicine
There is great interest in personalized medicine and it is clear
that personalized therapy requires combinations, since we cannot
develop a different drug for each patient. The information on the
state of the system that we suggest should be incorporated in the
algorithms can at the same time provide a molecular profile
corresponding to each effective combination. In other words an
omic-combination dictionary could be built listing the untreated
genomic, transcriptomic, proteomic and metabolomic profile
optimally responding to a drug combination, and this information
could guide therapy in individual patients.
The algorithms could be used not only to find optimal
combinations for specific diseases but also for individual patients
when repeated sampling is feasible, for example in studies of
chemosensitivity of cells from the blood of leukemia patients [39].
Conclusion
Novel technology for high-throughput screening and for omic
data measurements might allow us to develop new combined
pharmacological interventions adapting algorithmic and theoret-
ical approaches from more quantitative sciences
We report data from computational simulations and from
biological experiments in vivo and in cell culture, suggesting that
modified search algorithms from information theory have the
potential to enhance the discovery of novel optimal or near-
optimal therapeutic combinations.
It would be desirable to obtain a larger number of fully factorial
datasets, for different biological systems. This would allow a direct
comparison of the algorithms reported here with other reasonable
alternatives, such as stochastic algorithms. Fully factorial datasets
would be even more useful if they were to include system-wide
molecular (omic) data, at least for the single drug and for untreated
cases. While this might require a considerable experimental effort,
it would allow this area of research to be firmly established and
provide a resource for scientists with different algorithmic
backgrounds to test their ideas.
Several colleagues have already pointed out analogies with
other computational problems within their fields of expertise that
might lead to useful alternative approaches. For example a
colleague has suggested that exploring alternatives within the class
of ‘‘online algorithms’’ is a promising area of future work. Other
colleagues have proposed that modern biologically-inspired
heuristic methods, such as ‘‘particle swarm optimization’’, might
also be used to search for optimized drug combinations. In the
next few years we plan to obtain and make fully available on the
web additional fully factorial datasets for drug-induced selective
cell death, and we hope that this will stimulate interdisciplinary
interest in this approach to the problem of multi-drug therapy.
Methods
Drosophila Physiology
A detailed account of the Drosophila cardiac aging model was
presented previously, in which an age-dependent decline in
Drosophila cardiac rate under stress was reported [11]. We
developed new methods for imaging rapidly and non-invasively
the adult Drosophila heart and for automated measurement of heart
rate and its variability.
To assess exercise capacity in Drosophila and changes with age,
climbing velocity was measured using a method described by
Gargano et al. [40], modified to include image processing that
allowed individual flies to be studied.
The flies were transferred into 15-ml tubes and the operator
tapped the top of the tube. Owing to their capacity for geotaxis
orientation, flies tend to climb upwards. A digital imaging system/
camera (Motionscope PCI, Redlake Imaging MASD, Inc.) with an
attached Vivitar wide-angle lens, was used to capture video sequences
at 60 frames per second of the flies as they climbed the tube. Images
were analyzed with software (MotionScope 2.21.1) and for each fly
within the tube an individual velocity was obtained.
The selected compounds and doses (in the fly food) were:
doxycycline, with concentrations at 0.5 mg/mL and 1 mg/mL;
sodium selenite, at 0.005 mg/mL and 0.0125 mg/mL; zinc
sulfate, at 0.5 mg/mL and 1 mg/mL; and resveratrol, at
0.25 mM and 0.5 mM.
Figure 10. The most general algorithmic approach. The loop of
biological testing and ranking indicates the algorithms described in
detail in the Results. The mechanistic models are examples from our
recent publications [1,38] and the system-wide molecular data (omic
data), to be collected for individual interventions, represent microarrays
and NMR metabolomics. The arrows indicate a flux of information from
the system wide molecular data. The network or pathway models and
the rankings are incorporating this information but they are not
uniquely determined by it. The models are also built using legacy data
from the literature and the rankings are produced by the algorithms
described in the Results.
doi:10.1371/journal.pcbi.1000249.g010
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The data sets, used to test the SS9 and SS-TD9 algorithms, were
created using the apoptosis model [1], with some changes concerning
the search procedure and the output value. Instead of performing an
exhaustive search on all the nodes of the network, we limited the
search to a randomly chosen subgroup of nodes. We also used as
output value the difference of the cubic value of one individual
compared to the average of the cubic sum of the remaining
population, to reward the individuals with the highest values.
Confirmatory simulations were also performed, to test the
robustness of our findings by changing several parameters. The
parameters were the number of states for nodes and links, the
starting values for the states, the ranges of the output of the
simulation, and the nodes selected for the interventions.
The software was written in C++ and implemented on 32-nodes
of a 64-bit Linux cluster with 2GB of memory per node. The
longest searches required about 30 minutes of computation.
The analysis of the collected data consisted of three separated
steps: sort, search algorithm and statistical analysis. For the first
step, a quick sort implementation was used creating different ranks
for each individual. In the second step, all the algorithms and
random execution returned information for each rank. These were
used in the last step, where we collected the statistical analysis data,
dividing the resulting population into different samples, to
compare each algorithm with the others.
Owing to the dimension of the data, it was necessary to limit the
number of analyzed nodes to a maximum of 9. Computational
time was significant only for the sorter, requiring several hours for
the largest files on an entry-level Linux workstation.
Cancer Cells
ATP is a marker for cell viability because it is present in all
metabolically active cells and the concentration declines very
rapidly when the cells undergo necrosis or apoptosis. Human
tumor cells DOHH2 and RS11846 were maintained as suspension
cultures at standard conditions: humidified atmosphere with 5%
carbon dioxide, at 37uC in an incubator, using RPMI-1640
medium, supplemented with 10% heat-inactivated fetal calf serum
and 2 mM L-glutamine. Cells were kept in log phase via
replacement of cellular suspension aliquots by fresh medium two
or three times weekly. Stock solutions of the 6 chosen drugs were
freshly prepared in water (Vincristine), physiological saline solution
(Rituximab) or DMSO (Etoposide, Q-VD-Oph, Apogossypol and
Dexamethasone). The stock solutions were diluted with RPMI-
1640 in order to obtain the desired final concentrations. Less than
0.5% of the solvent was present at the final dilutions. All the
procedures related to cell culture, drug preparation, and treatment
were carried out in a laminar flow cabinet.
Briefly, exponentially growing cells were seeded in 96-well plates
(90 mL aliquots/well) at a density of 5.55 10
4 cells/mL and 10 mL
of drug solution were added. Final concentrations of the drug were
the following: Vincristine (0.01, 0.1, or 0.5 nM), Etoposide (0.01,
0.1, or 1 mM), Apogossypol (1, 2.5, or 4 mM), Q-VD-OPh (5, 10,
or 25 mM), Rituximab (5,15, or 20 mg/mL), Dexamethasone
(0.1,1, or 25 mM). Plates were incubated for 60 hours. After the
incubation, 30 mL aliquots of ATPlite reconstituted reagent
(Perkin-Elmer) were added to every well. The plates were shaken
for 3 minutes at 750 rpm (Eppendorf MixMate). The absorption
of the samples was measured using a monolight 3096 microplate
luminometer (BD). Ten mL of a 10 mM ATP solution was added
to every well as internal standard. The plates were shaken for
2 minutes at 750 rpm and read.
Selectivity was defined as the difference in % survival between
the two cell types.
Statistical Analysis
All results are expressed as mean6standard error of the mean.
For comparisons of 2 groups unpaired t tests were used (non-
parametric tests were also significant) and for comparison of more
than 2 groups we used one-way analysis of variance with
Bonferroni correction for post-test comparisons. The Drosophila
data presented in Figure 1 were analyzed using the chi square test
for trends and results were confirmed using one-way analysis of
variance with linear test for trend. The number of combinations in
the introduction was obtained using Newton’s Binomial series up
to the 6
th order. The statistical software used was Prism
(GraphPad).
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